Filing Details
- Accession Number:
- 0000899243-21-005157
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-02-08 16:05:16
- Reporting Period:
- 2021-02-04
- Accepted Time:
- 2021-02-08 16:05:16
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1596946 | Quotient Ltd | QTNT | In Vitro & In Vivo Diagnostic Substances (2835) | 264719797 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1604628 | Jeremy Stackawitz | C/O Quotient Limited 28 Esplanade St Helier Y9 JE2 3QA | Chief Commercial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Ordinary Shares | Disposition | 2021-02-04 | 30,000 | $5.14 | 112,926 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct |
Reported Derivative Holdings
Sec. Name | Sec. Type | Price | Date | Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
---|---|---|---|---|---|---|---|
Ordinary Shares | Employee Stock Option (right to buy) | $11.92 | 2026-05-31 | 20,000 | 20,000 | Direct | |
Ordinary Shares | Employee Stock Option (right to buy) | $15.17 | 2025-05-19 | 22,500 | 22,500 | Direct | |
Ordinary Shares | Employee Stock Option (right to buy) | $8.00 | 2024-04-29 | 60,000 | 60,000 | Direct | |
Ordinary Shares | Employee Stock Option (right to buy) | $7.58 | 2027-05-23 | 40,000 | 40,000 | Direct | |
Ordinary Shares | Restricted Stock Units | $0.00 | 10,321 | 10,321 | Direct | ||
Ordinary Shares | Restricted Stock Units | $0.00 | 23,333 | 23,333 | Direct | ||
Ordinary Shares | Restricted Stock Units | $0.00 | 45,000 | 45,000 | Direct | ||
Ordinary Shares | Ordinary Share Option (Right to Buy) | $4.72 | 2030-10-31 | 30,000 | 30,000 | Direct |
Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
---|---|---|---|
2026-05-31 | 20,000 | 20,000 | Direct |
2025-05-19 | 22,500 | 22,500 | Direct |
2024-04-29 | 60,000 | 60,000 | Direct |
2027-05-23 | 40,000 | 40,000 | Direct |
10,321 | 10,321 | Direct | |
23,333 | 23,333 | Direct | |
45,000 | 45,000 | Direct | |
2030-10-31 | 30,000 | 30,000 | Direct |
Footnotes
- All 20,000 options have vested and remain exercisable.
- All 22,500 options have vested and remain exercisable.
- All 60,000 options have vested and remain exercisable.
- All 40,000 options have vested and remain exercisable.
- Restricted Stock Units convert into ordinary shares on a one-for-one basis.
- On May 24, 2018, the Reporting Person was granted 30,961 Restricted Stock Units, of which 20,640 have vested and have been exercised. The remaining 10,321 Restricted Stock Units will vest on May 24, 2021.
- On May 24, 2019, the Reporting Person was granted 35,000 Restricted Stock Units, of which 11,667 have vested and have been exercised. The remaining 23,333 will vest in two equal installments on May 24, 2021 and May 24, 2022.
- On May 24, 2020, the Reporting Person was granted 45,000 Restricted Stock Units, vesting in three equal annual installments beginning May 24, 2021.
- The option vests and becomes exercisable in three equal annual installments beginning October 31, 2021.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.090 to $5.275, inclusive. The Reporting Person undertakes to provide to Quotient Limited and any security holder of Quotient Limited, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (10) to this Form 4.